Hinge Health gains as investors continue to respond to raised 2026 outlook

Hinge Health (HNGE) is up 6.6% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied mainly to continued investor optimism after Hinge Health raised its second-quarter and full-year 2026 guidance at its June 2026 investor event. Recent bullish target increases from Wall Street firms may also be helping support momentum in the shares.

Details:

Hinge Health said on June 9 that it raised full-year 2026 revenue guidance to $818 million to $824 million, an increase of $20 million at the midpoint from its prior range.

The company also lifted its second-quarter outlook, including revenue of $200 million to $202 million and stronger expected non-GAAP operating income.

Management pointed to continued business momentum, better member conversion, and stronger performance across its client base when explaining the higher forecast.

The company also used its investor event to highlight product expansion, including broader musculoskeletal care offerings that now extend into surgery coordination, which may be reinforcing the longer-term growth story.

Sources:

Hinge Health Investor Relations, Stock Analysis, SEC

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$HNGE Insider Trading Activity

$HNGE insiders have traded $HNGE stock on the open market 72 times in the past 6 months. Of those trades, 0 have been purchases and 72 have been sales.

Here’s a breakdown of recent trading of $HNGE stock by insiders over the last 6 months:

HOLDINGS GROUP, LLC INSIGHT has made 0 purchases and 24 sales selling 935,685 shares for an estimated $66,447,493.
GABRIEL M.I. MECKLENBURG has made 0 purchases and 17 sales selling 466,666 shares for an estimated $23,754,814.
DANIEL ANTONIO PEREZ (CEO & Co-Founder) has made 0 purchases and 3 sales selling 333,330 shares for an estimated $14,441,133.
JAMES PURSLEY (President) has made 0 purchases and 12 sales selling 79,000 shares for an estimated $4,371,767.
JAMES BUDGE (Chief Financial Officer) has made 0 purchases and 10 sales selling 32,457 shares for an estimated $1,406,853.
ELLIOTT ROBINSON has made 0 purchases and 6 sales selling 0 shares for an estimated $0.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive HNGE Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$HNGE Hedge Fund Activity

We have seen 132 institutional investors add shares of $HNGE stock to their portfolio, and 101 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

COATUE MANAGEMENT LLC removed 4,702,208 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $218,417,561
DEER MANAGEMENT CO. LLC added 2,633,707 shares (+inf%) to their portfolio in Q1 2026, for an estimated $101,555,741
FULLER & THALER ASSET MANAGEMENT, INC. added 1,655,198 shares (+inf%) to their portfolio in Q1 2026, for an estimated $63,824,434
RTW INVESTMENTS, LP added 1,576,500 shares (+446.0%) to their portfolio in Q1 2026, for an estimated $60,789,840
VANGUARD GROUP INC added 1,367,693 shares (+110.5%) to their portfolio in Q4 2025, for an estimated $63,529,339
AMERICAN CENTURY COMPANIES INC added 1,299,332 shares (+inf%) to their portfolio in Q1 2026, for an estimated $50,102,241
TIGER GLOBAL MANAGEMENT LLC added 1,253,743 shares (+227.1%) to their portfolio in Q4 2025, for an estimated $58,236,362

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$HNGE Analyst Ratings

Wall Street analysts have issued reports on $HNGE in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Needham issued a "Buy" rating on 02/11/2026
Canaccord Genuity issued a "Buy" rating on 02/11/2026
Barclays issued a "Overweight" rating on 01/05/2026

To track analyst ratings and price targets for $HNGE, check out Quiver Quantitative's $HNGE forecast page.

$HNGE Price Targets

Multiple analysts have issued price targets for $HNGE recently. We have seen 14 analysts offer price targets for $HNGE in the last 6 months, with a median target of $75.5.

Here are some recent targets:

Stan Berenshteyn from Wells Fargo set a target price of $90.0 on 06/24/2026
Vikram Kesavabhotla from Baird set a target price of $65.0 on 06/17/2026
Richard Close from Canaccord Genuity set a target price of $76.0 on 06/15/2026
Brian Peterson from Raymond James set a target price of $80.0 on 06/15/2026
Scott Schoenhaus from Keybanc set a target price of $90.0 on 06/12/2026
Ryan MacDonald from Needham set a target price of $76.0 on 06/11/2026
Saket Kalia from Barclays set a target price of $70.0 on 06/11/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.